Granahan Investment Management - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.

Quarter-by-quarter ownership
Granahan Investment Management ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2022$3,399,000
+12.4%
52,006
+4.5%
0.11%
+7.8%
Q2 2022$3,025,000
-47.7%
49,776
-46.0%
0.10%
-28.5%
Q1 2022$5,781,000
+60.4%
92,106
+93.7%
0.14%
+94.6%
Q4 2021$3,603,000
-29.0%
47,541
+4.9%
0.07%
-22.9%
Q3 2021$5,074,000
-38.9%
45,330
-11.6%
0.10%
-38.1%
Q2 2021$8,304,000
+41.2%
51,292
+6.2%
0.16%
+24.0%
Q1 2021$5,882,000
-32.8%
48,275
-15.6%
0.12%
-36.5%
Q4 2020$8,757,000
+166.2%
57,197
+45.4%
0.20%
+75.9%
Q3 2020$3,290,000
+2.6%
39,334
-9.8%
0.11%
-3.4%
Q2 2020$3,206,000
+121.6%
43,625
+27.8%
0.12%
+48.7%
Q1 2020$1,447,000
-31.3%
34,127
-1.3%
0.08%
-19.6%
Q4 2019$2,106,000
+48.5%
34,5820.0%0.10%
+24.4%
Q3 2019$1,418,000
-5.7%
34,582
+8.3%
0.08%
+5.4%
Q2 2019$1,504,000
+28.9%
31,927
-2.2%
0.07%
+17.5%
Q1 2019$1,167,000
+16.7%
32,657
-6.7%
0.06%
-11.3%
Q4 2018$1,000,000
-52.4%
34,992
-26.1%
0.07%
-37.7%
Q3 2018$2,100,000
-62.3%
47,342
-50.1%
0.11%
-66.1%
Q2 2018$5,570,000
+40.5%
94,791
+9.3%
0.34%
+17.5%
Q1 2018$3,965,000
+19.6%
86,743
-38.5%
0.29%
+9.6%
Q4 2017$3,314,000
-29.7%
141,140
-46.5%
0.26%
-33.6%
Q3 2017$4,713,000
+69.2%
263,746
+51.7%
0.39%
+52.9%
Q2 2017$2,786,000173,9070.26%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2022
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders